ABC ABCAM PLC

Abcam to present at the 2021 SVB Leerink Global Healthcare Conference

Abcam to present at the 2021 SVB Leerink Global Healthcare Conference

CAMBRIDGE, United Kingdom, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; LSE: ABC) today announced that Alan Hirzel, Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8.00 EST / 13.00 GMT. A live webcast of the presentation can be accessed via the IR Calendar page of Abcam’s Investor Relations website at .

Contact:

James Staveley, VP, Investor Relations

+44 (0) 1223 392 948

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam’s ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

For more information, please visit  or 



EN
17/02/2021

Underlying

ABCABCAM PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ABCAM PLC

Free Trial
ABC ABCAM PLC

Abcam: 1 director

A director at Abcam bought 15,000 shares at 15.410USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

05/03/22 May 3, 2022 1 EN
Free Trial
ABC ABCAM PLC

ABCAM sees an upgrade to Slightly Positive due to a better fundamental...

The general evaluation of ABCAM (GB), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 18, 2022, the closing price was GBp 1,359.00...

03/19/22 March 19, 2022 1 EN
 PRESS RELEASE
Free
ABC ABCAM PLC

Abcam Plc Results for the 12- and 18-month periods ended 31 December 2...

Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021 Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its final results for the 18-month period ended 31 December 2021 (the ‘period’). The Group’s accounting reference date changed ...

March 14, 2022 1 EN
 PRESS RELEASE
Free
ABC ABCAM PLC

29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually R...

29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six- and 12-month periods ended 30 June 2021 (the ‘period’). The Group’s accounting reference date has changed from 30 June to 31 December1, therefore these interim financial statements report on both a six- and 12-month per...

September 13, 2021 1 EN
 PRESS RELEASE
Free
ABC ABCAM PLC

Abcam to Acquire BioVision for $340 million

Abcam to Acquire BioVision for $340 million CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”). Transaction highlights BioVision is a fast-growing innovator and distributor of life science research tools to biopharma, diagnostic ...

August 2, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch